Edwards Lifesciences (EW) Accumulated Expenses (2009 - 2026)

Edwards Lifesciences has reported Accumulated Expenses for 18 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Accumulated Expenses rose 4.85% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 4.85% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 21.78% from the prior year.
• Accumulated Expenses was $1.3 billion for Q2 2026 at Edwards Lifesciences, up from $1.2 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $1.7 billion in Q3 2024, with the low at $739.5 million in Q3 2022.
• Average Accumulated Expenses over 5 years is $1.1 billion, with a median of $982.0 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 70.44% in 2024, then slipped 20.13% in 2025.
• Over 5 years, Accumulated Expenses stood at $795.0 million in 2022, then increased by 7.72% to $856.4 million in 2023, then soared by 49.74% to $1.3 billion in 2024, then increased by 21.78% to $1.6 billion in 2025, then declined by 18.47% to $1.3 billion in 2026.
• The last three Accumulated Expenses figures came in at $1.3 billion (Q2 2026), $1.2 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.